<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608944</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 58133</org_study_id>
    <nct_id>NCT02608944</nct_id>
  </id_info>
  <brief_title>Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging</brief_title>
  <official_title>Comparison of New MRI Methods for Quantitative Assessment of Myocardial Perfusion With Quantitative PET Perfusion Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This work seeks to develop, evaluate and use new MRI methods for non-invasive quantitative&#xD;
      assessment of myocardial perfusion and perfusion reserve (MPR), and to compare with&#xD;
      quantitative PET imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project aims to determine the validity of quantitative MRI perfusion methods by&#xD;
      comparison with quantitative PET imaging. First pass dynamic contrast enhanced MRI scans will&#xD;
      be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson.&#xD;
      After custom reconstruction and post-processing the data will be fit to a compartment model&#xD;
      and quantitative perfusion and MPR values obtained.&#xD;
&#xD;
      On another day, the subjects will have quantitative PET imaging with O-15 labeled radioactive&#xD;
      water. This will be done at rest and hyperemia caused by either adenosine or regadenoson. A&#xD;
      low dose CT scan will be acquired to perform attenuation correction of the PET images. The&#xD;
      images will be reconstructed and processed as reported in the literature to provide reference&#xD;
      standard perfusion and MPR values. These values will be compared with those obtained by MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    MRI perfusion techniques development took longer than expected.&#xD;
  </why_stopped>
  <start_date type="Actual">September 30, 2012</start_date>
  <completion_date type="Actual">June 12, 2019</completion_date>
  <primary_completion_date type="Actual">June 12, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial perfusion values from MRI</measure>
    <time_frame>The scan will take ~1-2 hours. The MRI will be done within 2 months of the PET scan.</time_frame>
    <description>Myocardial perfusion in segments and coronary territories will be computed in ml/min/g from the dynamic MRI data. The perfusion values will be compared to PET data to determine how similar the values are.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial perfusion values from PET</measure>
    <time_frame>The scan will take ~1-2 hours. The PET scan will be done within 2 months of the MRI.</time_frame>
    <description>Myocardial perfusion in segments and coronary territories will be computed in ml/min/g from the dynamic PET data. The perfusion values will be compared to MRI data to determine how similar the values are.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>MRI Scans</condition>
  <arm_group>
    <arm_group_label>MRI perfusion vs. PET Imaging perfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adenosine Regadenoson O-15 labeled radioactive water MRI PET Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion</description>
    <arm_group_label>MRI perfusion vs. PET Imaging perfusion</arm_group_label>
    <other_name>Adenoscan</other_name>
    <other_name>Adenocard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <description>Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.</description>
    <arm_group_label>MRI perfusion vs. PET Imaging perfusion</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O-15 labeled radioactive water</intervention_name>
    <description>O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging</description>
    <arm_group_label>MRI perfusion vs. PET Imaging perfusion</arm_group_label>
    <other_name>O-15 water</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson</description>
    <arm_group_label>MRI perfusion vs. PET Imaging perfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET Imaging</intervention_name>
    <description>Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.</description>
    <arm_group_label>MRI perfusion vs. PET Imaging perfusion</arm_group_label>
    <other_name>Positron Emission Tomography Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:&#xD;
&#xD;
               -  All participants will be over the age of 18 and able to provide consent&#xD;
&#xD;
               -  Both healthy and subjects with cardiac disease (including atrial fibrillation but&#xD;
                  not required) will be recruited.&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
               -  Critically ill patients, patients on ventilators, patients with unstable angina&#xD;
                  or with hypotension, asthmatics, and other patients whose medical care or safety&#xD;
                  may be at risk from undergoing an MRI examination will be excluded.&#xD;
&#xD;
               -  Patients with claustrophobia will also be excluded from the study if this cannot&#xD;
                  be controlled with standard methods (valium or benadryl).&#xD;
&#xD;
               -  Patients with contraindication to MRI (pacemaker, metal implants, or certain&#xD;
                  types of heart valves),&#xD;
&#xD;
               -  pregnant patients, minors, mentally disabled patients and prisoners will be&#xD;
                  excluded from this study. (All criteria apply to patients and normal volunteers).&#xD;
&#xD;
               -  Gadolinium nephrotoxicity will be addressed by having patients with abnormal&#xD;
                  kidney function (GFR&lt;30) excluded from the study due to the (very small) risk&#xD;
                  associated with gadolinium contrast agents. This threshold may be modified,&#xD;
                  depending on practices determined by the Radiology Department and the IRB.&#xD;
&#xD;
               -  Patients with a known allergy or contraindication to Adenosine and/or Regadenoson&#xD;
                  will be excluded from stress (hyperemia) cohorts.&#xD;
&#xD;
               -  All participants that will receive a stress agent will refrain from consuming&#xD;
                  caffeine for at least 12 hours prior to each study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward DiBella, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah, Radiology Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Edward DiBella</investigator_full_name>
    <investigator_title>Ph.D.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02608944/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

